NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Atezolizumab

Last Revision: December 3, 2018.

Estimated reading time: 1 minute

CASRN: 1380723-44-3

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of atezolizumab during breastfeeding. Because atezolizumab is a large protein molecule with a molecular weight of 145,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, atezolizumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during atezolizumab therapy and for at least 5 months after the last dose.

Atezolizumab is a human immunoglobulin G1 (IgG1) antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G in mature milk by 60 to 79%.[1][2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with IgG1 activity decreasing by about 37%.[3] None of the studies measured IgG activity.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Atezolizumab

CAS Registry Number

1380723-44-3

Drug Class

  • Breast Feeding
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Biological Response Modifiers
  • Immunologic Adjuvants
  • Immune Checkpoint Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Similar articles in PubMed

  • Review Durvalumab[Drugs and Lactation Database (...]
    Review Durvalumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Bezlotoxumab[Drugs and Lactation Database (...]
    Review Bezlotoxumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Avelumab[Drugs and Lactation Database (...]
    Review Avelumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ipilimumab[Drugs and Lactation Database (...]
    Review Ipilimumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Emapalumab[Drugs and Lactation Database (...]
    Review Emapalumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...